Cover Image
市場調查報告書

(癲癇的)部份性發作開發中產品分析

Partial Seizure - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 213088
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
(癲癇的)部份性發作開發中產品分析 Partial Seizure - Pipeline Review, H2 2015
出版日期: 2015年12月16日 內容資訊: 英文 95 Pages
簡介

所謂(癲癇的)部份性發作,是指腦部只有部分放電發作。部分性發作的致病要素有癲癇、腦瘤、感染疾病、中風、低血糖等各種要素。主要症狀有臉頰潮紅和嘔吐、肌肉反覆地收縮和緩和、腹痛、心跳急速上升等。主要治療方法為抗癲癇藥等。

本報告提供全球各國治療部份性發作用的開發中產品之開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

部份性發作概要

治療藥的開發

  • 部份性發作開發中產品:概要
  • 部份性發作開發中產品:比較分析

各企業開發中的部份性發作治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

部份性發作治療藥:開發中產品一覽(各企業)

部份性發作治療藥的開發企業

  • Novartis AG
  • Eisai
  • Pfizer Inc.
  • UCB S.A.
  • Marinus Pharmaceuticals, Inc.
  • Bial - Portela & Ca, S.A.
  • SciFluor Life Sciences, LLC
  • SK Biopharmaceuticals Co., Ltd.

部份性發作:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 分子類別

藥物簡介

  • lacosamide
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • levetiracetam
  • eslicarbazepine acetate
  • brivaracetam
  • perampanel
  • carisbamate
  • pregabalin CR
  • Remegal
  • YKP-3089
  • selurampanel
  • ganaxolone
  • SF-0034

部份性發作治療藥:開發中產品的最新趨勢

部份性發作治療藥:暫停開發的產品

部份性發作治療藥:中止開發的產品

部份性發作相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7469IDB

Summary

Global Markets Direct's, 'Partial Seizure - Pipeline Review, H2 2015', provides an overview of the Partial Seizure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Partial Seizure
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Partial Seizure and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Partial Seizure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Partial Seizure pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Partial Seizure
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Partial Seizure pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Partial Seizure Overview
  • Therapeutics Development
    • Pipeline Products for Partial Seizure - Overview
  • Partial Seizure - Therapeutics under Development by Companies
  • Partial Seizure - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Partial Seizure - Products under Development by Companies
  • Partial Seizure - Companies Involved in Therapeutics Development
    • Advicenne Pharma
    • Catalyst Pharmaceutical Partners, Inc.
    • Eisai Co., Ltd.
    • Marinus Pharmaceuticals, Inc.
    • Novartis AG
    • SciFluor Life Sciences, LLC
    • SK Biopharmaceuticals Co., Ltd.
    • UCB S.A.
  • Partial Seizure - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • brivaracetam - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clobazam - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CPP-115 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ganaxolone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lacosamide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levetiracetam - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MB-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • perampanel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selurampanel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SF-0034 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YKP-3089 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Partial Seizure - Recent Pipeline Updates
  • Partial Seizure - Dormant Projects
  • Partial Seizure - Discontinued Products
  • Partial Seizure - Product Development Milestones
    • Featured News & Press Releases
      • Nov 02, 2015: Eisai Presents Results From Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy for Refractory Partial-Onset Seizures Conducted in Asia Including Japan
      • Apr 20, 2015: Important UCB presents data on VIMPAT at the 2015 American Academy of Neurology Meeting
      • Jan 05, 2015: Phase III Trial of Antiepileptic Drug Perampanel As Adjunctive Therapy In Patients With Refractory Partial-Onset Seizures Conducted In Asia Including Japan And China Meets Primary Endpoint
      • Dec 08, 2014: UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy
      • Apr 25, 2014: Eisai Presents Research on FYCOMPA (perampanel) CIII at The American Academy of Neurology's 66th Annual Meeting
      • Feb 10, 2014: Fycompa to be Resubmitted Early to German Federal Joint Committee for Additional Benefit Assessment
      • Jan 06, 2014: Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S.
      • Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older
      • Nov 20, 2013: New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Partial Seizure, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Partial Seizure - Pipeline by Advicenne Pharma, H2 2015
  • Partial Seizure - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015
  • Partial Seizure - Pipeline by Eisai Co., Ltd., H2 2015
  • Partial Seizure - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015
  • Partial Seizure - Pipeline by Novartis AG, H2 2015
  • Partial Seizure - Pipeline by SciFluor Life Sciences, LLC, H2 2015
  • Partial Seizure - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
  • Partial Seizure - Pipeline by UCB S.A., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Partial Seizure Therapeutics - Recent Pipeline Updates, H2 2015
  • Partial Seizure - Dormant Projects, H2 2015
  • Partial Seizure - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Partial Seizure, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top